益气养阴解毒方联合奥希替尼一线治疗EGFR突变晚期非小细胞肺癌(CATLA-2)双盲随机对照试验方案
本研究为双盲、多中心随机对照试验方案,计划纳入314例EGFR Ex19del或L858R突变的晚期非小细胞肺癌患者,随机分配至奥希替尼联合益气养阴解毒方组或奥希替尼联合安慰剂组,主要终点为无进展生存期,旨在评估联合治疗的有效性与安全性。
要点
- EGFR突变晚期NSCLC初治患者可考虑奥希替尼联合益气养阴解毒方。
- 该方案为双盲随机对照试验,主要终点为无进展生存期。
- 次要终点包括总生存期、客观缓解率、疾病控制率和生活质量。
核心结论
- 本试验旨在评估益气养阴解毒方联合奥希替尼一线治疗EGFR突变阳性晚期NSCLC的有效性和安全性。
研究设计与样本
- 双盲、多中心、随机对照试验,在中国八家医院开展,计划纳入314例受试者。
关键数值与推荐
- 入组标准为确诊晚期NSCLC且携带EGFR Ex19del或L858R突变、准备接受奥希替尼一线治疗、年龄18-74岁并签署知情同意书。
- 主要终点为无进展生存期(PFS),次要终点包括总生存期(OS)、客观缓解率(ORR)、疾病控制率(DCR)和生活质量(QoL)。
- 分析基于意向性治疗和符合方案集原则。
临床怎么用
- 为EGFR突变晚期NSCLC患者一线使用奥希替尼时联合益气养阴解毒方提供高级别循证依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the prognosis of non-small cell lung cancer (NSCLC) with EGFR mutation-positive. Although third-generation EGFR-TKI osimertinib is demonstrated with superior efficacy compared with first-generation EGFR-TKIs, acquired resistance to EGFR-TKIs remains the bottleneck. The Chinese herbal medicine (CHM) Yiqi-Yangyin-Jiedu decoction (YYJD) has been shown to delay acquired resistance to first-generation EGFR-TKIs in the CATLA study, but there is no high-level evidence for its effect when combined with osimertinib. This trial aims to evaluate the efficacy and safety of YYJD combined with osimertinib as first-line treatment in EGFR mutation-positive advanced NSCLC. Methods: This is a double-blind, multi-center, randomized controlled trial conducted in eight hospitals in China. A total of 314 participants will be randomly assigned to the osimertinib plus YYJD group (O+YYJD) or the osimertinib plus placebo group (O+placebo). Treatment will last until disease progression or death. Patients diagnosed with advanced NSCLC harboring EGFR Ex19del or L858R will be enrolled if they are ready to take osimertinib as first-line treatment, aged 18-74 years old, and provide signed informed consent. The primary outcome is progression-free survival (PFS). The secondary outcomes include a comparison of overall survival (OS), objective response rate (ORR), disease control rate (DCR), and quality of life (QoL). The analysis will be based on intention-to-treat and per-protocol subject analysis principles. Discussion: The goal of this trial is to evaluate the efficacy and safety of YYJD when added to osimertinib as first-line treatment in EGFR mutation-positive advanced NSCLC.
引用
- Yao J, Lu Y, Jiao L, et al. Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial. Front Pharmacol. 2022. PMID: 35431966. doi:10.3389/fphar.2022.840889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。